Psoriasis Disease Pipeline Drugs Assessment
Psoriasis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
(EMAILWIRE.COM, March 24, 2018 ) Psoriasis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Psoriasis Disease Pipeline Drugs Assessment
Overview:
Psoriasis is a genetic inflammatory diseases which affects skin. Psoriasis is characterised by skin cells that multiply up to 10 times faster than normal. When these cells reach surface and die, raised, red plaques covered with white scales for. Psoriasis begins as a small scaling papule. When multiple papules coalesce, they form scaling plaques. These plaques tend to occur in the scalp, elbows, and knees.
Symptoms includes red patches on skin, small scaling spots, dry and cracked skin, burning, itching and soreness of skin, bleeding etc. Psoriasis is diagnosed by physical examination and skin biopsy. Psoriasis is treated by topical corticosteroids, Vitamin D analogues, Topical retinoid, Calcineurin inhibitors etc. and it can be treated by phototherapy
A sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By Trial Phase, Psoriasis pipeline drugs are segmented as:
Preclinical Trials
Phase 1
Phase 2
Phase 3
Phase 4
By Company, Psoriasis pipeline drugs are segmented as:
Galderma
Arcutis, Inc.
Almirall, S.A.
proDERM GmbH
Novartis Pharmaceuticals
GlaxoSmithKline
Janseen
AbbVie
Boehringer Ingelheim
Others
By Drugs, Psoriasis pipeline drugs are segmented as:
Icotinib Hydrochloride
Bimekizumab
Calcipotriene
Ustekinumab
Risankizumab
Methotrexate
Others
By Type of Condition, Psoriasis pipeline drugs are segmented as:
Plaque psoriasis
Scalp psoriasis
Guttate psoriasis
Nail psoriasis
Inverse psoriasis
Pustular psoriasis
Erythrodermic psoriasis
Psoriatic arthritis
By Route of Administration, Psoriasis pipeline drugs are segmented as:
Oral
Parenteral
To view TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
In November 2016,Janssen-Cilag submitted Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of CNTO 1959 (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis
In March 2016, Dr. Reddys Laboratories and XenoPort, Inc. entered into a license agreement pursuant to which Dr. Reddys Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPorts clinical-stage oral new chemical entity, XP23829. Dr. Reddys Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis
Report Description:
Psoriasis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Psoriasis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Psoriasis disease pipeline drugs development. This report studies the dynamics of the Psoriasis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Psoriasis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
Provides the information related to universities and research institutes working in the therapeutics development
Report comprehensively covers the all active and discontinued studies
Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
Presents the prominent targets for drug development in each stage of clinical trial
Provides the in-depth analysis on the each drug candidates in the clinical trial phases
Get access to full summary @https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @https://www.precisionbusinessinsights.com
Psoriasis Disease Pipeline Drugs Assessment
Overview:
Psoriasis is a genetic inflammatory diseases which affects skin. Psoriasis is characterised by skin cells that multiply up to 10 times faster than normal. When these cells reach surface and die, raised, red plaques covered with white scales for. Psoriasis begins as a small scaling papule. When multiple papules coalesce, they form scaling plaques. These plaques tend to occur in the scalp, elbows, and knees.
Symptoms includes red patches on skin, small scaling spots, dry and cracked skin, burning, itching and soreness of skin, bleeding etc. Psoriasis is diagnosed by physical examination and skin biopsy. Psoriasis is treated by topical corticosteroids, Vitamin D analogues, Topical retinoid, Calcineurin inhibitors etc. and it can be treated by phototherapy
A sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By Trial Phase, Psoriasis pipeline drugs are segmented as:
Preclinical Trials
Phase 1
Phase 2
Phase 3
Phase 4
By Company, Psoriasis pipeline drugs are segmented as:
Galderma
Arcutis, Inc.
Almirall, S.A.
proDERM GmbH
Novartis Pharmaceuticals
GlaxoSmithKline
Janseen
AbbVie
Boehringer Ingelheim
Others
By Drugs, Psoriasis pipeline drugs are segmented as:
Icotinib Hydrochloride
Bimekizumab
Calcipotriene
Ustekinumab
Risankizumab
Methotrexate
Others
By Type of Condition, Psoriasis pipeline drugs are segmented as:
Plaque psoriasis
Scalp psoriasis
Guttate psoriasis
Nail psoriasis
Inverse psoriasis
Pustular psoriasis
Erythrodermic psoriasis
Psoriatic arthritis
By Route of Administration, Psoriasis pipeline drugs are segmented as:
Oral
Parenteral
To view TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
In November 2016,Janssen-Cilag submitted Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of CNTO 1959 (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis
In March 2016, Dr. Reddys Laboratories and XenoPort, Inc. entered into a license agreement pursuant to which Dr. Reddys Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPorts clinical-stage oral new chemical entity, XP23829. Dr. Reddys Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis
Report Description:
Psoriasis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Psoriasis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Psoriasis disease pipeline drugs development. This report studies the dynamics of the Psoriasis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Psoriasis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
Provides the information related to universities and research institutes working in the therapeutics development
Report comprehensively covers the all active and discontinued studies
Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
Presents the prominent targets for drug development in each stage of clinical trial
Provides the in-depth analysis on the each drug candidates in the clinical trial phases
Get access to full summary @https://www.precisionbusinessinsights.com/market-reports/psoriasis-disease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @https://www.precisionbusinessinsights.com
Contact Information:
Precision Business Insights
Satya Satya
Tel: 866-598-1553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Precision Business Insights
Satya Satya
Tel: 866-598-1553
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results